Citation Impact
Citing Papers
Proteomic Markers of DNA Repair and PI3K Pathway Activation Predict Response to the PARP Inhibitor BMN 673 in Small Cell Lung Cancer
2013
Reciprocal Regulation of DUSP9 and DUSP16 Expression by HIF1 Controls ERK and p38 MAP Kinase Activity and Mediates Chemotherapy-Induced Breast Cancer Stem Cell Enrichment
2018 StandoutNobel
PARP inhibitors: Synthetic lethality in the clinic
2017 StandoutScience
Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
2017 Standout
Pharmacokinetic Properties of 2′-O-(2-Methoxyethyl)-Modified Oligonucleotide Analogs in Rats
2001
Dendritic cells in cancer immunology and immunotherapy
2019 Standout
EGFR Antagonists in Cancer Treatment
2008 Standout
Chemosensitivity linked to p73 function
2003 StandoutNobel
Costs and Effects of Abdominal versus Laparoscopic Hysterectomy: Systematic Review of Controlled Trials
2009
Spatio-temporal Dynamics of Protein Kinase B/Akt Signaling Revealed by a Genetically Encoded Fluorescent Reporter
2004 StandoutNobel
K-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
2008 Standout
The RB and p53 pathways in cancer
2002 Standout
The PARP1 inhibitor BMN 673 exhibits immunoregulatory effects in a Brca1 −/− murine model of ovarian cancer
2015
A Randomized, Double-Masked, Placebo-Controlled Study of Alicaforsen, an Antisense Inhibitor of Intercellular Adhesion Molecule 1, for the Treatment of Subjects With Active Crohn’s Disease
2007
Issues and progress with protein kinase inhibitors for cancer treatment
2003
PARP inhibitors for BRCA1/2-mutated and sporadic ovarian cancer: current practice and future directions
2016
The Urokinase Plasminogen Activator System: A Target for Anti-Cancer Therapy
2009
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
2008 Standout
A matter of life and death
2002 Standout
Inflammatory bowel disease: clinical aspects and established and evolving therapies
2007 Standout
Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and Cardiotoxicity
2004 Standout
xCell: digitally portraying the tissue cellular heterogeneity landscape
2017 Standout
Quality of Life in Long-Term, Disease-Free Survivors of Breast Cancer: a Follow-up Study
2002 Standout
Recurrence Rates after Treatment of Breast Cancer with Standard Radiotherapy with or without Additional Radiation
2001 Standout
From molecular biology to nanotechnology and nanomedicine
2002
Therapeutic application of small interfering RNA directed against bcr-abl transcripts to a patient with imatinib-resistant chronic myeloid leukaemia
2007
New insights into the mechanisms of epithelial–mesenchymal transition and implications for cancer
2018 Standout
The Bcl2 family: regulators of the cellular life-or-death switch
2002 Standout
Advances of capillary electrophoresis in clinical and forensic analysis (1999-2000)
2001
The role of new agents in the treatment of non-small cell lung cancer
2002
Biological Functions of Autophagy Genes: A Disease Perspective
2019 Standout
Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles
2010 StandoutNature
Anticancer activities of histone deacetylase inhibitors
2006 Standout
Cancer genes and the pathways they control
2004 Standout
Phase II trial with ISIS 5132 in patients with small-cell (SCLC) and non-small cell (NSCLC) lung cancer. A European Organization for Research and Treatment of Cancer (EORTC) Early Clinical Studies Group report
2001
Dendrimers in biomedical applications—reflections on the field
2005 Standout
Antisense therapy for cancer
2005
Targeting the IL-6/JAK/STAT3 signalling axis in cancer
2018 Standout
Targeting RAS signalling pathways in cancer therapy
2003 Standout
Treatment of HIV-associated Kaposi's sarcoma with paclitaxel
1995
Involvement of PI3K/Akt pathway in cell cycle progression, apoptosis, and neoplastic transformation: a target for cancer chemotherapy
2003
Oncomirs — microRNAs with a role in cancer
2006 Standout
UALCAN: A Portal for Facilitating Tumor Subgroup Gene Expression and Survival Analyses
2017 Standout
Raf kinases: Oncogenesis and drug discovery
2006
Apoptosis
2002 Standout
Antisense therapy in oncology: new hope for an old idea?
2001
Regulation and Function of the PD-L1 Checkpoint
2018 Standout
Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer
2007 Standout
MicroRNA therapeutics: towards a new era for the management of cancer and other diseases
2017 Standout
Overview of the clinical efficacy of investigational anticancer drugs
2003
Phase I Trial Design for Solid Tumor Studies of Targeted, Non-Cytotoxic Agents: Theory and Practice
2004
STAT proteins: novel molecular targets for cancer drug discovery
2000
Use of Reverse Phase Protein Microarrays and Reference Standard Development for Molecular Network Analysis of Metastatic Ovarian Carcinoma
2005
Cellular delivery of antisense oligonucleotides
2000
Tumor metastasis: mechanistic insights and clinical challenges
2006 Standout
The STATs of cancer — new molecular targets come of age
2004 Standout
Tackling the cancer stem cells — what challenges do they pose?
2014
The Bcl-2 apoptotic switch in cancer development and therapy
2007 Standout
The PI3K Pathway in Human Disease
2017 Standout
Using sulfuramidimidoyl fluorides that undergo sulfur(vi) fluoride exchange for inverse drug discovery
2020 StandoutNobel
Kaposi's Sarcoma
2000 Standout
Side Effects of Adjuvant Treatment of Breast Cancer
2001
Antisense therapeutics: lessons from early clinical trials
2001
Tumorigenesis and the angiogenic switch
2003 Standout
Principles of Cancer Therapy: Oncogene and Non-oncogene Addiction
2009 Standout
Circadian clock disruption improves the efficacy of chemotherapy through p73-mediated apoptosis
2011 StandoutNobel
The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data
2012 Standout
Potential roles of antisense technology in cancer chemotherapy
2000
Microfluidics: Fluid physics at the nanoliter scale
2005 Standout
Antiangiogenic and antitumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells.
2000
Laying a trap to kill cancer cells: PARP inhibitors and their mechanisms of action
2016
Review of Phase II Trial Designs Used in Studies of Molecular Targeted Agents: Outcomes and Predictors of Success in Phase III
2008
Diabetes and Cancer
2010 Standout
Green synthesis of metal nanoparticles using plants
2011 Standout
Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal
2013 Standout
Antisense treatment directed against mutated Ki-ras in human colorectal adenocarcinoma
2001
Nucleic-acid therapeutics: basic principles and recent applications
2002
Targeting Signal Transduction Pathways in Colorectal Cancer—More Than Skin Deep
2005
Phase II randomized study of ISIS 3521 and ISIS 5132 in patients with locally advanced or metastatic colorectal cancer: a National Cancer Institute of Canada clinical trials group study.
2002
Activatable Photosensitizers for Imaging and Therapy
2010 Standout
Surgical approach to hysterectomy for benign gynaecological disease
2015 Standout
Role of the Vascular Endothelial Growth Factor Pathway in Tumor Growth and Angiogenesis
2004 Standout
Works of Andrew Dorr being referenced
Phase II study of CGP 69846A (ISIS 5132) in recurrent epithelial ovarian cancer: an NCIC clinical trials group study (NCIC IND.116)☆
2003
A Phase I trial of h-ras antisense oligonucleotide ISIS 2503 administered as a continuous intravenous infusion in patients with advanced carcinoma
2001
A Phase II trial of aprinocarsen, an antisense oligonucleotide inhibitor of protein kinase C α, administered as a 21‐day infusion to patients with advanced ovarian carcinoma
2004
Phase I Evaluation of ISIS 3521, an Antisense Oligodeoxynucleotide to Protein Kinase C-Alpha, in Patients With Advanced Cancer
1999
Abstract P2-09-02: BMN 673 is a PARP inhibitor in clinical development for the treatment of breast cancer patients with deleterious germline BRCA 1 and 2 mutations
2013
Paclitaxel (Taxol) in Breast Cancer
1994
Results of a phase 2 study of pacritinib (SB1518), a JAK2/JAK2(V617F) inhibitor, in patients with myelofibrosis
2015
The role of laparoscopic hysterectomy and lymph node dissection in treatment of endometrial cancer.
1999
Phase I study of an antisense oligonucleotide to protein kinase C-alpha (ISIS 3521/CGP 64128A) in patients with cancer.
1999
Abstract C295: Update on first-in-man trial of novel oral PARP inhibitor BMN 673 in patients with solid tumors.
2013
First-in-human trial of novel oral PARP inhibitor BMN 673 in patients with solid tumors.
2013
A randomized phase II and pharmacokinetic study of the antisense oligonucleotides ISIS 3521 and ISIS 5132 in patients with hormone-refractory prostate cancer.
2002
A phase I trial of c-Raf kinase antisense oligonucleotide ISIS 5132 administered as a continuous intravenous infusion in patients with advanced cancer.
2000
Prediction of Clinical Responses in a Simulated Phase III Trial of Crohn's Patients Administered the Antisense Phosphorothioate Oligonucleotide ISIS 2302: Comparison of Proposed Dosing Regimens
2003
O-108 Randomized phase III trial of chemotherapy and antisense oligonucleotide LY900003 (ISIS 3521) in patients with advanced NSCLC
2003